Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer
- 1 May 1997
- Vol. 49 (5) , 668-672
- https://doi.org/10.1016/s0090-4295(97)00084-8
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The PSA nadir that indicates potential cure after radiotherapy for prostate cancerUrology, 1997
- Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer.Journal of Clinical Oncology, 1996
- Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinomaCancer, 1996
- Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiationCancer, 1995
- The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical ProstatectomyJournal of Urology, 1994
- PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiationInternational Journal of Radiation Oncology*Biology*Physics, 1994
- SERUM PSA AFTER ANATOMIC RADICAL PROSTATECTOMYUrologic Clinics of North America, 1993
- Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostateUrology, 1993
- Is Prostate Specific Antigen of Clinical Importance in Evaluating Outcome after Radical ProstatectomyJournal of Urology, 1993
- Failure of Open Radioactive 125 Iodine Implantation to Control Localized Prostate Cancer: A Study of 41 PatientsJournal of Urology, 1991